CNBC: Bayer, J&J settle blood thinner Xarelto litigation for $775 million

On Monday, court documents revealed that Bayer and Johnson & Johnson agreed to settle more than 25,000 U.S. lawsuits over their blood thinner Xarelto for $775 million. However, Bayer and J&J did not have to admit liability under the agreement.

RELATED STORY:

• CNN: Bayer is cutting 12,000 jobs in the wake of its Monsanto deal

In what should not come as a shock to anyone, both Bayer and Johnson & Johnson continue to believe the claims are without merit (they have blinders on about everything). J&J also added that the “settlement was the right thing to do for patients and their doctors.”¹

RELATED STORY:

• CNN: Johnson & Johnson shares plunge after report that says it knew about asbestos in its baby powder

“The settlement will resolve all pending U.S. lawsuits over Xarelto, which plaintiffs claimed causes uncontrollable and irreversible bleeding leading to severe injuries and even death among thousands of plaintiffs.

Plaintiffs accused the drugmakers of having failed to warn about the bleeding risks, claiming their injuries could have been prevented had doctors and patients been provided adequate information.”¹

Xarelto is Bayer’s best-selling drug, contributing $4.07 billion in revenue to the German group’s pharmaceutical business last year. And J&J reported their 2018 Xarelto sales at $2.47 billion.

RELATED STORY:

• Black Box Drugs: What to know & what you can do

Have you ever taken Xarelto and had problems? If you are still taking it, talk to your doctor before stopping taking it.

SOURCE:

1. CNBC